European Union - English - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastic agents - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment.adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy.adult patients with relapsed or refractory ph+ all as monotherapy.adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements.adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement.the effect of imatinib on the outcome of bone marrow transplantation has not been determined.imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist).the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatment.the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery.in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5.1). except in newly diagnosed chronic phase cml, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

Malta - English - Medicines Authority

koanaa healthcare gmbh fehrgasse 7, 2401, fischamend,, austria - pemetrexed - concentrate for solution for infusion - pemetrexed 100 mg - antineoplastic agents

Malta - English - Medicines Authority

koanaa healthcare gmbh fehrgasse 7, 2401, fischamend,, austria - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

koanaa healthcare limited - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - 20 milligram(s)/millilitre - other antineoplastic agents; irinotecan

Ireland - English - HPRA (Health Products Regulatory Authority)

koanaa healthcare limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Ireland - English - HPRA (Health Products Regulatory Authority)

koanaa healthcare limited - imatinib mesylate - film-coated tablet - 100 milligram(s) - protein kinase inhibitors; imatinib

Ireland - English - HPRA (Health Products Regulatory Authority)

koanaa healthcare limited - imatinib mesylate - film-coated tablet - 400 milligram(s) - protein kinase inhibitors; imatinib

Malta - English - Medicines Authority

koanaa healthcare limited - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 40/2 milligram(s)/millilitre - antineoplastic agents

Malta - English - Medicines Authority

koanaa healthcare limited - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 100 milligram(s)/5 millilitre - antineoplastic agents

Malta - English - Medicines Authority

koanaa healthcare limited - irinotecan hydrochloride, trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 300/15 milligram(s)/millilitre - antineoplastic agents